Research programme: allergen vaccines - Circassia

Drug Profile

Research programme: allergen vaccines - Circassia

Alternative Names: Allergen desensitisation - Circassia; Allergen immunotherapy - Circassia

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Circassia
  • Class Epitopes; Subunit vaccines
  • Mechanism of Action Immunosuppressants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Hypersensitivity

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Allergy in United Kingdom (Intradermal, Injection)
  • 30 Jul 2012 Preclinical development is ongoing for Hypersensitivity to birch pollen, & early research is ongoing for Hypersensitivity to Alternaria spp., Japanese cedar pollen & dog dander
  • 20 Jul 2010 Preclinical development is ongoing in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top